Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of “Moderate Buy” by Brokerages

Kura Oncology, Inc. (NASDAQ:KURA) has earned an average recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $25.4615.

A number of brokerages have recently commented on KURA. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 4th. Jefferies Financial Group set a $24.00 target price on Kura Oncology in a report on Thursday, May 28th. Oppenheimer set a $24.00 target price on Kura Oncology in a research report on Thursday, May 28th. Sanford C. Bernstein set a $24.00 target price on Kura Oncology in a report on Monday, June 15th. Finally, CLSA set a $24.00 target price on Kura Oncology in a report on Thursday, June 4th.

Kura Oncology Price Performance

Shares of NASDAQ KURA opened at $9.19 on Tuesday. The stock has a market cap of $815.80 million, a P/E ratio of -2.74 and a beta of 0.38. The firm’s 50-day simple moving average is $10.15 and its 200 day simple moving average is $9.27. Kura Oncology has a fifty-two week low of $5.45 and a fifty-two week high of $12.49. The company has a quick ratio of 6.14, a current ratio of 6.15 and a debt-to-equity ratio of 0.09.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. The firm had revenue of $18.27 million for the quarter, compared to analysts’ expectations of $25.97 million. Equities analysts expect that Kura Oncology will post -3.45 EPS for the current year.

Insider Buying and Selling

In related news, insider Mollie Leoni sold 84,929 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the completion of the transaction, the insider owned 182,345 shares of the company’s stock, valued at approximately $1,790,627.90. This trade represents a 31.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 7.60% of the company’s stock.

Institutional Trading of Kura Oncology

A number of hedge funds have recently modified their holdings of the business. IFP Advisors Inc grew its holdings in shares of Kura Oncology by 115.3% during the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after buying an additional 1,284 shares in the last quarter. Allworth Financial LP lifted its stake in Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after acquiring an additional 1,553 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Kura Oncology by 49.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock worth $60,000 after acquiring an additional 1,888 shares during the period. Tower Research Capital LLC TRC boosted its position in Kura Oncology by 471.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after acquiring an additional 9,958 shares during the period. Finally, Brevan Howard Capital Management LP purchased a new position in Kura Oncology during the 2nd quarter valued at about $80,000.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.